TY  - JOUR
T1  - EXperimental malaria vaccine
AU  - Friedrich MJ
Y1  - 2012/12/19
N1  - 10.1001/jama.2012.128613
JO  - JAMA
SP  - 2449
EP  - 2449
VL  - 308
IS  - 23
N2  - 
In the phase 3 trial, 6537 infants who were between 6 and 12 months old at the time of the first vaccination received 3 doses of either the RTS,S/AS01 candidate vaccine or a nonmalaria comparator vaccine at 1-month intervals along with standard childhood vaccines. An analysis of the incidence of malaria in infants for 12 months after the third vaccine dose found that the RTS,S/AS01 vaccine reduced the risk of detectable malaria and severe malaria by 31% and 37%, respectively, compared with controls.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.128613
UR  - http://dx.doi.org/10.1001/jama.2012.128613
ER  -